항암제를 투여한 HeLa와 OVCAR-3 세포주에서 Cytokeratin 18-Asp(396) (M30) 항체를 이용한 항암제 감수성의 측정 = Detection of chemosensitivity using K18-Asp396 (M30) antibody in HeLa and OVCAR-3 cell Lines treated with anticancer agents

다국어 초록 (Multilingual Abstract)

Objective: The aim of this study was to detect the levels of M30-antigens as a biomarker of apoptosis in cells and their culture media after treatments with anticancer drugs as a preclinical study. Methods: After HeLa and OVCAR-3 cells were treated respectively with paclitaxel, cisplatin, and camptothecin, the harvested cells were stained sequentially with M30 monoclonal antibodies and propidium iodide (PI). Afterwards, they were analyzed using a FACScan flow cytometer and observed under an immunofluorescence microscope for M30-FITC immunofluorescences. Levels of M30 antigens were also detected in their culture media using M30-Apoptosense ELISA kit. Results: The levels of M30-FITC immunofluorescences were elevated in both cell lines after each drug treatments compared with those of control cells. The levels of M30 antigens detected by ELISA in media culturing each cell line treated with each of drugs were elevated compared with those of control cells. Conclusion: This study suggests that M30-antigens representing chemotherapy induced apoptosis may be a useful biomarker for predicting and monitoring the response of neoadjuvant chemotherapy in patients with gynecologic cancers.

참고문헌 (Reference)

1 Richardson ME, "Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance" 39 : 789-795, 1997

2 Napolitano U, "The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial" 24 : 51-59, 2003

3 Darzynkiewicz Z, "The cell cycle effects of camptothecin" 803 : 93-100, 1996

4 Woods CM, "Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway" 1 : 506-526, 1995

5 Corver WE, "Simultaneous measurement of two cellular antigens and DNA using fluorescein- isothiocyanate, phycoerythrin and propidium iodide on a standard FACScan" 15 : 117-128, 1994

6 Goossens JF, "Relation between intracellular acidification and camptothecin- induced apoptosis in leukemia cells" 10 : 125-131, 2000

7 Wang TH, "Paclitaxel- induced cell death : Where the cell cycle and apoptosis come together" 88 : 2619-2628, 2000

8 Ayhan A, "Neoadjuvant chemotherapy in gynecological cancers" 27 : 11-15, 2006

9 Han KT, "Multiparametric flow cytometry in breast cancer cell line (MCF-7) stained with fluorescein isothiocyanate, phycoerythrin, and propidium iodide" 31 : 1129-1139, 1999

10 Ormerod MG, "Investigating the relationship between the cell cycle and apoptosis using flow cytometry" 265 : 73-80, 2002

11 Leers MP, "Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis" 187 : 567-572, 1999

12 Kramer G, "Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18" 64 : 1751-1756, 2004

13 Ueno T, "Detection of epithelial cell death in the body by cytokeratin 18 measurement" 59 (59): 359-362, 2005

14 Linder S, "Cytokeratin Markers Come of Age" 28 : 189-195, 2007

15 Ricci MS, "Chemotherapeutic approaches for targeting cell death pathways" 11 : 342-357, 2006

16 Untch M, "Chemosensitivity testing in gynecologic oncology--dream or reality?" 161 : 146-158, 2003

17 Wang D, "Cellular processing of platinum anticancer drugs" 4 : 307-320, 2005

18 Maddika S, "Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy" 10 : 13-29, 2007

19 Tiezzi DG, "Apoptosis induced by neoadjuvant chemotherapy in breast cancer" 38 : 21-27, 2006

20 Gibb RK, "Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines" 65 : 13-22, 1997